ONK Therapeutics Announces $21.5M Series A Financing to Adva

$21.5 million Series A round led by current investors Acorn Bioventures and ALSHC, joined by new investor Cormorant Asset Management Financing will drive multiple pre-clinical programs through

Related Keywords

Australia , Ireland , Seamus Mulligan , Kostenloser Wertpapierhandel , Isaac Manke , Randy Phillips , Sue Charles , Ray Gordon , Linkedin , Therapeutics Inc , Eliza Hall Institute Of Medical Research , Acorn Bioventures , Cormorant Asset Management , Cormorant Asset , Cell Lung Cancer , Managing Director , Michaelo Dwyer , Eliza Hall Institute , Medical Research , Therapeutics , Nnounces , Series , Financing , Advance , Pipeline , Text , Generation , Optimally , Engineered , Shelf , Fell , Therapies ,